KIRKLAND, WA, November 18, 2015—Aminex Therapeutics, Inc., developer of a first-in-class suppressor cell modulator cancer immunotherapy, today announced the addition of Dr. Steven Weitman and Dr. Philippe Bey to its Scientific Advisory Board (SAB).
“We are very fortunate and delighted to have these two distinguished gentlemen join our SAB,” stated Jim Skaggs, chief executive officer and chairman of Aminex Therapeutics. “Both have enjoyed long, accomplished drug development careers with extensive experience that is directly applicable to Aminex’s goal of confirming its patented lead drug, AMX-513, in human clinical trials planned to start in mid-2016.”
Dr. Bey was the designer and inventor of difluoromethylornithine (DFMO), one of the two components of Aminex’s AMX-513 combination drug. He is currently senior vice president of R&D at Thrasos Therapeutics, a private Canadian clinical-stage biotechnology company.
Dr. Weitman is director of the Institute for Drug Development at the Cancer Therapy and Research Center, an NCI-designated Cancer Center, at the University of Texas Health Science Center at San Antonio. Dr. Weitman also worked with DFMO in his early career and has been an advisor for neuroblastoma clinical trials using DFMO.
Drs. Bey and Weitman recently attended their first Aminex SAB meeting with Dr. Michael Palfreyman, chairman of the SAB and Aminex’s senior VP of drug development; existing SAB members Dr. Paul Schechter and Dr. Robert Lewis; and Dr. Mark Burns, Aminex’s chief scientific officer and drug inventor. Drs. Palfreyman and Schechter were also key players on the DFMO team 30 years ago, and Dr. Burns developed Aminex’s AMX-513 drug combination. These six provide the strong foundation of scientific capability and drug development experience that guides Aminex’s plan and work, much of which is performed by an array of highly experienced drug research consultants and contractors.
Additional information on the SAB members can be found on Aminex’s website, referenced below.
About Aminex Therapeutics, Inc.
Aminex Therapeutics, Inc. is a drug development company focused on discovery, development, and commercialization of suppressor cell modulators (SCMs), a new class of small molecule cancer immunotherapies which enable the immune system to attack cancer by regulating myeloid-derived suppressor cells. Aminex has extensively demonstrated, in animal trials, the potential of its lead drug, AMX-513, to be effective alone and to improve overall therapy when used in combination with other cancer treatments. Aminex’s vision is to make significant treatment contributions for a wide range of cancers and to ease rising costs of cancer therapy.
For more information, please visit www.aminextx.com.